The New South Wales Therapeutic Advisory Group Inc. (NSW TAG) is an independent, not-for-profit member-based organisation, comprised of clinical pharmacologists, pharmacists, nurses and clinicians committed to advancing quality use of medicines (QUM) in NSW public hospitals and the wider community.

We seek to facilitate processes that ensure consumers of health care in NSW receive the most appropriate medicines in the most appropriate manner whilst ensuring that the limited resources of the health care budget devoted to medicines use are used according to sound economic principles.

In pursuing this goal, we focus on providing information, advice and support to decision-makers in NSW public hospitals, NSW Ministry of Health and other relevant organisations.

Our goal is:

  • To advance quality use of medicines by sharing unbiased, evidence-based information about drug therapy

Our objectives are:

    • To investigate and evaluate new initiatives in therapeutics
    • To support Drug and Therapeutics Committees
  • To promote rational, high quality, cost-effective use of medicines in public hospitals and the wider community

NSW TAG has applied the following strategies to achieve these objectives:

    • To develop position statements and evidence-based guidelines for the rational use of specific drugs and drug groups
    • To collect and analyse quantitative and qualitative drug usage data
    • To develop and utilise specific strategies to influence prescribing behaviour and provide a counter-balance to industry promotion
    • To describe and monitor the activities and decision-making of drug committees to¬†facilitate equity, increase transparency and to promote peer review/support
    • To assess the impact of new¬†medicines on quality of patient care in the hospital system
    • To disseminate information to stakeholders and educate identified target groups
    • To provide advice on therapeutic matters to NSW Health
    • To undertake projects on behalf of NSW Health according to availability of resources
    • To conduct and facilitate research pertinent to the quality use of medicines
  • To facilitate provision of economic analyses and critical appraisal of pharmacoeconomic studies